Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Cell Physiol ; 235(2): 1711-1722, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31304601

RESUMEN

Multifarious biological functions of long noncoding RNAs (lncRNAs) have been reported in various cancers including bladder cancer (BCa). This study aims to determine the biological role of a certain lncRNA in BCa. Consistent with the data of The Cancer Genome Atlas database, it was validated that lncRNA HLA complex group 22 (HCG22) was weakly expressed in BCa samples and lowly expressed HCG22 was closely correlated with low overall survival of the BCa patient. To verify the role of HCG22 in BCa progression, functional experiments were carried out in two representative BCa cells (J82 and T24) and the negative effects of HCG22 expression on the cell proliferation, migration, and epithelial-mesenchymal transition were identified. Mechanistically, polypyrimidine tract-binding protein 1 (PTBP1), which was highly expressed in BCa tissues and cell lines, was negatively regulated by HCG22 and the PTBP1-mediated Warburg effect was also obstructed by HCG22. Furthermore, HCG22 modulated the expression of PTBP1 through destabilizing human antigen R (HuR). And functional rescue assays confirmed that HCG22 functioned in bladder cancer through downregulating PTBP1. In conclusion, the present study revealed that HCG22 inhibited BCa progression via the HuR/PTBP1 axis, opening new prospects for potent therapeutic regimens for BCa patients.


Asunto(s)
Regulación Neoplásica de la Expresión Génica/genética , Regulación de la Expresión Génica/genética , Ribonucleoproteínas Nucleares Heterogéneas/biosíntesis , Proteína de Unión al Tracto de Polipirimidina/biosíntesis , ARN Largo no Codificante/genética , Neoplasias de la Vejiga Urinaria/patología , Adulto , Anciano , Línea Celular Tumoral , Proliferación Celular/genética , Proteína 1 Similar a ELAV/biosíntesis , Proteína 1 Similar a ELAV/genética , Transición Epitelial-Mesenquimal/genética , Femenino , Ribonucleoproteínas Nucleares Heterogéneas/genética , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica/genética , Proteína de Unión al Tracto de Polipirimidina/genética , Neoplasias de la Vejiga Urinaria/genética
2.
World J Surg Oncol ; 15(1): 169, 2017 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-28886717

RESUMEN

BACKGROUND: Association between dietary protein intake and colorectal cancer risk has not been fully quantified, while the results were controversial. This study aimed to evaluate the role of protein intake in the development of colorectal cancer. METHODS: PUBMED and EMBASE were searched up to December 2016. Two independent reviewers independently extracted data from eligible studies. Relative risk (RR) with 95% confidence intervals (CI) was pooled using random-effects model to estimate the result. Besides, publication bias and sensitivity analysis were conducted. RESULTS: Thirteen articles involving 21 studies comprising 8187 cases were included in this report. The pooled RR of colorectal cancer was 1.006 (95% CI = 0.857-1.179) indicating that there is no significant association between dietary protein intake and colorectal cancer risk. Furthermore, the pooled RRs for colon cancer and rectum cancer were 1.135(95% CI = 0.871-1.480) and 0.773(95% CI = 0.538-1.111), respectively, with the highest category of dietary protein intake. The association was not significant either in subgroup analysis of study design, protein type (animal protein or vegetable protein), sex, and or geographic locations. CONCLUSIONS: The present study indicated that the highest category compared to the lowest category of protein intake had no significant association on colorectal cancer risk. Dose-response analysis was not conducted due to limited information provided. Therefore, more studies with large cases and participants as well as detailed amounts of dietary protein intake are wanted to confirm this result.


Asunto(s)
Neoplasias del Colon/epidemiología , Proteínas en la Dieta , Conducta Alimentaria , Neoplasias del Recto/epidemiología , Humanos , Incidencia , Factores de Riesgo
3.
Eur J Gastroenterol Hepatol ; 26(11): 1217-21, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25187299

RESUMEN

OBJECTIVES: The prevalence of fundic gland polyps (FGPs) is increasing. Some researchers consider this increase to be associated strongly with the long-term use of proton-pump inhibitors (PPIs); however, not all researchers share this belief. There are minimal data on the development of FGPs in China. Therefore, we aimed to investigate the prevalence of FGPs and risk factors associated with the development of this disease. MATERIALS AND METHODS: We studied 10 904 consecutive patients who underwent gastroduodenal endoscopies at our digestive endoscopy center between February 2011 and January 2013. Information on sex, age, Helicobacter pylori infection, PPIs intake, and the pathological results of the polyps were collected in the FGPs group and in the control group. The use of PPIs, sex, and H. pylori infection were statistically evaluated as dichotomous variables using a χ-test; age was evaluated as a continuous variable using a t-test. Finally, these factors were evaluated using a multiple logistic regression analysis. RESULTS: Gastric polyps were found in 759 (7.0%) patients, and 213 (2.0%) of these patients had FGPs. FGPs accounted for 28.1% of the gastric polyps. In the FGPs group, the percentage of H. pylori infection was 66.8% and the percentage of PPIs intake for at least 12 months was 23.1%. In the control group, the percentage of H. pylori infection was 77.4% and the percentage of PPIs intake for at least 12 months was 2.3%. The difference in the long-term use of PPIs was statistically significant between these two groups [χ=33.98, P<0.05, odds ratio (OR)=12.83, 95% confidence interval (CI): 4.47-36.80]. The results of the logistic regression were as follows: long-term use of PPIs (P<0.01, OR=14.11, 95% CI: 4.15-47.93); age (P<0.01, OR=1.69, 95% CI: 1.31-2.18). The P-values for sex and H. pylori infection were higher than 0.05. CONCLUSION: Age and the long-term use of PPIs were risk factors for the presence of FGPs; the long-term use of PPIs was a particularly strong risk factor.


Asunto(s)
Pólipos/epidemiología , Neoplasias Gástricas/epidemiología , Adulto , Factores de Edad , China/epidemiología , Esquema de Medicación , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Fundus Gástrico , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Humanos , Masculino , Persona de Mediana Edad , Pólipos/inducido químicamente , Pólipos/microbiología , Prevalencia , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Neoplasias Gástricas/inducido químicamente , Neoplasias Gástricas/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...